Tricon Capital Group Announces US$103.5 Million Investment to Develop an Active Adult Community in Phoenix, Arizona Canada NewsWire
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISTRIBUTION IN THE UNITED STATES ./ TORONTO , Oct.
JERUSALEM, Israel , December 3, 2014 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has received $5 million in connection with the definitive agreement with Guangxi Wuzhou Pharmaceutical Co., Ltd., a subsidiary of Guangxi Wuzhou Zhongheng Group Company Ltd (SHA:600252) previously reported on November 3, 2014 , for the purchase of 696,378 restricted shares of common stock for $7.18 per share, the closing price of Oramed's common stock on Friday, October 31, 2014 , in a private placement.
- Proposal coincides with Banbury coffee plant's 50th anniversary - Planned investment highlights success of Tassimo single-serve beverage system
- Part of a multi-year, $1.5 billion investment in European manufacturing BANBURY, England, Nov.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.